Special Issue "Advances in Parkinsonian Disorders"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: 25 May 2023 | Viewed by 831

Special Issue Editor

Department of Neurology and the Movement Disorders Unit, Shaare Zedek Medical Center, Jerusalem, Israel
Interests: Parkinson's disease; genetics; botulinum toxin; gait analysis

Special Issue Information

Dear Colleagues,

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. As of yet, due to available symptomatic treatment, an adequate level of quality of life may be maintained until the very advanced stages of the disorder. Despite the advancements in knowledge of the pathological processes associated with the degeneration leading to PD, there are some challenging aspects without adequate relief, such as dementia, levodopa-resistant freezing of gait, and postural instability.

This Special Issue of the Journal of Clinical Medicine will cover the following important items:

  • Gait assessment of PD, focusing on freezing of gait.
  • Physical activity for PD.
  • Non-dopaminergic therapy for PD.
  • Non-motor advances in PD, with a preference for cognitive disturbances.
  • Microbiome study.
  • Palliative care for PD.

Dr. Gilad Yahalom
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Parkinson's disease
  • gait analysis
  • physical activity
  • non-dopaminergic treatment
  • cognitive
  • microbiome
  • palliative care

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Reproductive Lifespan and Motor Progression of Parkinson’s Disease
J. Clin. Med. 2022, 11(20), 6163; https://doi.org/10.3390/jcm11206163 - 19 Oct 2022
Viewed by 658
Objectives: Estrogen not only plays a key role in the decreased risk of Parkinson’s disease (PD) but also influences its severity. We aimed to explore the effect of the reproductive lifespan on the motor progression of PD female patients in a large prospective [...] Read more.
Objectives: Estrogen not only plays a key role in the decreased risk of Parkinson’s disease (PD) but also influences its severity. We aimed to explore the effect of the reproductive lifespan on the motor progression of PD female patients in a large prospective cohort study. Methods: A competing risk analysis with a Fine and Gray model on 491 female and 609 male patients with PD was conducted. We regarded the chance of faster motor progression (as measured by the Unified Parkinson’s Disease Rating Scale (UPDRS) III increasing by ≥16 points during follow-up) and the chance of death as competing risks. The reproductive lifespan was regarded as the variable of interest, while faster motor progression was set as the primary outcome. Results: In the multivariable competing risk analysis, the male sex was not significantly associated with faster motor progression (subdistribution hazard ratio (SHR) 0.888, 95% CI 0.652–1.209, p = 0.450), while a shorter reproductive lifespan was associated with faster motor progression in women (SHR 0.964, 95% CI 0.936–0.994, p = 0.019). Sensitivity analysis indicated that a shorter reproductive lifespan was also significantly associated with faster motor progression in the 48 female patients who reported menopause after the onset of PD (SHR 0.156, 95% CI 0.045–0.542, p = 0.003). A linear mixed model also revealed the significant main effects of a short reproductive lifespan on the higher UPDRS III score in PD female patients at the last visit (p = 0.026). Conclusions: Our study indicates that a short reproductive lifespan contributes to faster motor progression in PD female patients, which has important implications for understanding the role of endogenous estrogen exposure in female PD and is beneficial to select appropriate patients in clinical trials. Full article
(This article belongs to the Special Issue Advances in Parkinsonian Disorders)
Show Figures

Figure 1

Back to TopTop